RT Journal Article
T1 Androgen receptor as prognostic marker in triple-negative breast cancer patients
A1 Cabezas Quintario, María Antonia
A1 Zenzola, Víctor
A1 Arguelles, Miguel
A1 Pérez Fernández, Elia
AB Purpose: The purpose of this study was to assess the prognostic impact of androgen receptor (AR) expression inpatients with triple-negative breast cancer (TNBC).Methods/patients: 101 patients treated for primary TNBC without distant metastasis from 1999 to 2015 wereidentified from breast surgery database. Kaplan-Meier and Cox regression models evaluated disease-free survival(DFS) and overall survival (OS).Results: AR expression was positive (IHC>1%) in 40% of patients. OS at 36 and 60 months was 86% and 80%in AR-negative patients, and 100% and 96% in AR-positive patients (log rank test 0.036). DFS at 36 and 60 monthswas 78% and 68% in AR-negative and 92% and 89% in AR-positive (log rank test 0.075).Conclusions: Patients without AR expression have a significant correlation with poor outcome
PB Longdom Group
SN 2472-4971
YR 2018
FD 2018-10-31
LK https://hdl.handle.net/20.500.14352/116473
UL https://hdl.handle.net/20.500.14352/116473
LA eng
NO MA Cabezas-Quintario, V Zenzola, M Arguelles, E Perez-Fernandez. Androgen Receptor as Prognostic Marker in Triple-Negative Breast Cancer Patients. Journal of Medical & Surgical Pathology [Internet]. 2018;03(04). Available from: http://dx.doi.org/10.4172/2472-4971.1000170
DS Docta Complutense
RD 12 abr 2025